Pfizer
Prescription medicines, vaccines and consumer products.
Launch date
Employees
Market cap
AUD255.4b
Enterprise valuation
AUD350.5b (Public information from Sep 2024)
Share price
$29.75 PFE
New York City New York (HQ)
Corporate Venture Fund: Pfizer Ventures
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 41.9b | 81.3b | 100.3b | 58.5b | 61.0b | 63.1b | 63.6b |
| % growth | (19 %) | 94 % | 23 % | (42 %) | 4 % | 3 % | 1 % |
| EBITDA | 14.1b | 28.5b | 43.6b | 14.4b | 22.3b | 24.3b | 25.4b |
| % EBITDA margin | 34 % | 35 % | 43 % | 25 % | 37 % | 38 % | 40 % |
| Profit | 9.6b | 22.0b | 31.4b | 2.1b | 6.6b | 10.4b | 11.4b |
| % profit margin | 23 % | 27 % | 31 % | 4 % | 11 % | 17 % | 18 % |
| EV / revenue | 5.5x | 4.2x | 3.0x | 3.8x | 3.7x | 3.5x | 3.3x |
| EV / EBITDA | 16.5x | 11.9x | 6.9x | 15.3x | 10.0x | 9.0x | 8.3x |
| R&D budget | 9.4b | 13.8b | 11.4b | 10.7b | - | - | - |
| R&D % of revenue | 22 % | 17 % | 11 % | 18 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $5.0m | Grant | |
$1.9b | Grant | ||
$2.0b | Grant | ||
* | N/A | $31.0b | Post IPO Debt |
| Total Funding | AUD6.0b | ||
Related Content
Recent News about Pfizer
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
By Industry
exited
ACQUISITION by Covidien Mar 2012
exited
ACQUISITION by Novartis Dec 2016
ACQUISITION by Pfizer Jul 2016
ACQUISITION by Pfizer Mar 2023
ACQUISITION by Pfizer Aug 2021